JPMorgan on Biogen (BIIB) in 2026: 'Watching Pipeline Derisking Through the Year'
Tweet Send to a Friend
JPMorgan analyst Chris Schott reiterated a Neutral rating and $175.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "Ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
